Genomics

By decoupling the enzyme from proprietary adapters, a new partnership aims to solve the reproducibility crisis in custom genomic and single-cell workflows.

As new clinical data debuts at CNS 2026, the intersection of advanced multi-omic tools and state Medicaid policy signals a new era for pediatric care.

As UPMC wins a top patient safety award for genomic surveillance, diagnostic startups are leveraging academic ties to prove WGS can deliver a 3.2x ROI.

As commercial sperm banks expand genetic testing to include adult-onset cancer risks, prospective parents face a new frontier of complex, life-altering data.

By mandating hereditary cancer testing for all new sperm donors, Xytex is pushing the fertility industry into complex ethical and legal territory.

Latvia's recent US trade mission secured strategic partnerships with defense and biotech giants, positioning the Baltic nation as a high-tech proving ground.

MyOme’s integration with Oracle Cloud marks a strategic shift in preventive healthcare, moving from single-use panels to lifetime genomic risk re-querying.

Ontario's publicly funded fetal DNA screening replaces universal injections with precision medicine, optimizing healthcare resources and securing Canada's blood supply.

As Western genomic giants stumble, Tokyo's A.D.A.M. Innovations leverages a 2.9 million-strong database and wearable tech to redefine predictive healthcare.

The Genome Partnership's latest awards aren't just accolades; they're a roadmap. See how ten emerging scientists are leading the charge into AI-driven healthcare.

Kala Bio's new deal with Virotek isn't just about eye care. It's a capital-efficient pivot that tests its new identity and bets on a commercial present.

By appointing two legendary specialists, XGEN isn't just shuffling its board. It's aiming to legitimize whole genome sequencing for all IVF patients.

A $10M federal contract aims to slash the 7-year wait for rare disease diagnoses. Discover how Probably Genetic's AI and direct-to-patient data are leading the charge.

A landmark UCSF study has mapped the molecular machinery of autism, revealing convergent pathways. This isn't just a breakthrough for ASD; it's a new model for drug discovery.

A landmark study reveals that children of centenarians inherit a powerful biological advantage, rewriting our understanding of aging, health, and longevity.

A new partnership merges genetic screening and sperm analysis, promising empowered family planning. But as data deepens, are we crossing an ethical frontier?

A shocking $90M guidance cut and a securities probe at Myriad Genetics reveal more than a bad quarter; they expose deep cracks in the genetic testing market.

Colossal Foundation's rewilding fund offers cash and genetic tech to save seven species. But can a $250k budget tackle a $5M problem and prove its model?

A reported net loss obscures core growth at 10x Genomics. An acquisition, key partnerships, and a blockbuster product launch signal a decisive strategic pivot.

With a new $345 genome and major clinical wins, PacBio pushes boundaries. But can its strategic restructuring and bold R&D overcome mounting financial losses?